Pharma News

The latest developments from pharmaceutical and biopharmaceutical companies, both innovator and generic-drug companies, and leading regulatory news.

Sanofi has agreed to acquire Kymab, a Cambridge, UK-based biopharmaceutical company, in a $1.45-billion deal ($1.1 billion upfront and up to $350 million in milestones). Kymab’s lead product is KY1005, in Phase IIa development, for treating atopic...

Sanofi has chosen the name EUROAPI for its new European company dedicated to the development, production and marketing of active pharmaceutical ingredients (APIs). Sanofi announced the formation of the standalone company in February 2020. The new...

Novartis has signed a strategic collaboration agreement to in-license from BeiGene, a Beijing-based pharmaceutical company, in major markets outside of China, tislelizumab, a drug for treating classical Hodgkin’s lymphoma and metastatic urothelial...

As part of ongoing divestment program of non-core assets following its $62-billion acquisition of Shire in 2019, Takeda Pharmaceutical has moved forward with two additional divestment deals totaling a combined $844 million. In the first deal,...

Moderna, a clinical-stage biopharmaceutical company developing messenger RNA (mRNA) therapeutics and vaccines, reports that the European Commission (EC), Health Canada, the pharmaceutical regulatory body of Canada, and Israel’s Ministry of Health...

Pfizer and BioNTech, a Mainz, Germany-based immunotherapy company, have been granted conditional marketing authorization (CMA) from the European Commission (EC) for their COVID-19 vaccine, making it the first COVID vaccine to receive a CMA in the...

The US Food and Drug Administration’s (FDA) has authorized the emergency use of Moderna’s vaccine against COVID-19 in individuals 18 years of age or older, making it the second vaccine against COVID-19 authorized for emergency use in the US. On...